<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322423</url>
  </required_header>
  <id_info>
    <org_study_id>CR-5860</org_study_id>
    <nct_id>NCT03322423</nct_id>
  </id_info>
  <brief_title>Evaluation of Two Marketed Multifocal Contact Lenses</brief_title>
  <official_title>Evaluation of Two Marketed Multifocal Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-masked, randomized, cross-over, dispensing, 6- visit pilot study. The
      purpose of this clinical study is to evaluate the performance of two marketed multifocal
      lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Actual">November 4, 2017</completion_date>
  <primary_completion_date type="Actual">November 4, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance Binocular Visual Acuity</measure>
    <time_frame>1-Week Follow-up</time_frame>
    <description>Distance visual acuity was assessed for each subject in both eyes under a high luminance high contrast condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Near Binocular Visual Acuity</measure>
    <time_frame>1-Week Follow-up</time_frame>
    <description>Near visual acuity was assessed for each subject in both eyes under a high luminance high contrast condition using reduced Guillon-Poling Charts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Quality of Vision</measure>
    <time_frame>1-Week Follow-up</time_frame>
    <description>Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Visual Performance</condition>
  <arm_group>
    <arm_group_label>Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 1 Multifocal then Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power), for approximately 8-12 days of wear with an approximately 4-8 day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power) then Test 1 Multifocal, for approximately 8-12 days of wear with an approximately 4-8 day washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multifocal Contact Lens 1</intervention_name>
    <description>Dailies Total 1 Multifocal Contact Lens</description>
    <arm_group_label>Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative</arm_group_label>
    <arm_group_label>Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal</arm_group_label>
    <other_name>Test 1 Multifocal , delefilcon A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multifocal Contact Lens 2</intervention_name>
    <description>Biotrue ONEday for Presbyopia Contact Lenses</description>
    <arm_group_label>Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative</arm_group_label>
    <arm_group_label>Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal</arm_group_label>
    <other_name>Test 2 Multifocal, nesofilcon A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spherical Contact Lens 2</intervention_name>
    <description>BioTrue ONEDay Spherical</description>
    <arm_group_label>Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative</arm_group_label>
    <arm_group_label>Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal</arm_group_label>
    <other_name>Test 2 Alternative, nesofilcon A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Potential subjects must satisfy all of the following criteria to be enrolled in the
             study:

               1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and
                  receive a fully executed copy of the form.

               2. The subject must appear able and willing to adhere to the instructions set forth
                  in this clinical protocol.

               3. The subject must be between at least 40 years of age and not greater than 70
                  years of age.

               4. The subject's distance spherical equivalent refraction must be in the range of
                  +3.75 D to -3.75 D.

               5. The subject's refractive cylinder must be ≤ -0.75 D in each eye.

               6. The subject's ADD power must be in the range of +0.75 D to +2.50 D in each eye.

               7. The subject must have best corrected visual acuity of 20/20-3 or better in each
                  eye.

               8. The subject must own a pair of wearable spectacles if required for their distance
                  vision.

               9. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn
                  lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1
                  month or more duration).

              10. The subject must either be wearing a presbyopic contact lens correction (e.g.,
                  reading spectacles over contact lenses, multifocal or monovision contact lenses,
                  etc.) or respond positively to at least one symptom on the &quot;Presbyopic Symptoms
                  Questionnaire&quot;.

                  Exclusion Criteria:

          -  Potential subjects who meet any of the following criteria will be excluded from
             participating in the study:

               1. Ocular or systemic allergies or disease, or use of medication which might
                  interfere with contact lens wear.

               2. Pregnancy or lactation.

               3. Currently diagnosed with diabetes.

               4. Infectious diseases (e.g. hepatitis, tuberculosis) or an immune-suppressive
                  disease (e.g. HIV).

               5. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization,
                  corneal staining, tarsal abnormalities or bulbar injection, or any other corneal
                  or ocular abnormalities which would contraindicate contact lens wear.

               6. Entropion, ectropion, extrusions, chalazia, recurrent styes, dry eye, glaucoma,
                  history of recurrent corneal erosions.

               7. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy,
                  PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.).

               8. A history of amblyopia, strabismus or binocular vision abnormality.

               9. Any ocular infection or inflammation.

              10. Any ocular abnormality that may interfere with contact lens wear.

              11. Use of any ocular medication, with the exception of rewetting drops.

              12. History of herpetic keratitis.

              13. Participation in any contact lens or lens care product clinical trial within 30
                  days prior to study enrollment.

              14. Employee of clinical site (e.g., Investigator, Coordinator, Technician)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Golden Vision</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ABQ Eye Care</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacco Eye Group</name>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <zip>13850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Bay Eye Associates</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02888</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Botetourt Eyecare, LLC</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <results_first_submitted>October 31, 2018</results_first_submitted>
  <results_first_submitted_qc>December 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03322423/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 78 subjects were enrolled into this study. Of the enrolled all 78 were dispensed at least one study lens. Of the dispensed subjects 71 completed the study, while 7 subjects were discontinued.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Delefilcon A/Nesofilcon A</title>
          <description>All subjects that were randomized to receive the delefilcon A lens during the first period of the study and the nesofilcon A lens during the second period of the study.</description>
        </group>
        <group group_id="P2">
          <title>Nesofilcon A/Delefilcon A</title>
          <description>All subjects that were randomized to receive the nesofilcon A during the first period of the study and the delefilcon A lens during the second period of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject no longer eligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect Lens Dispensed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Lens Fitting</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Dispensed incorrect lens in left eye</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject not eligible for Pytergiumectomy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Dispensed Subjects</title>
          <description>All subjects that were dispensed a study lens.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Distance Binocular Visual Acuity</title>
        <description>Distance visual acuity was assessed for each subject in both eyes under a high luminance high contrast condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts.</description>
        <time_frame>1-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Delefilcon A</title>
            <description>All subjects that wore the delefilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Nesofilcon A</title>
            <description>All subjects that wore the nesofilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Distance Binocular Visual Acuity</title>
          <description>Distance visual acuity was assessed for each subject in both eyes under a high luminance high contrast condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.0842"/>
                    <measurement group_id="O2" value="-0.075" spread="0.0759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Statistical superiority was concluded if the upper limit of the confidence intervals of the Test lens was below +0.01 logMAR for distance.</non_inferiority_desc>
            <param_type>Least-Square Mean Estimate</param_type>
            <param_value>-0.058</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.080</ci_lower_limit>
            <ci_upper_limit>-0.035</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Statistical superiority was concluded if the upper limit of the confidence intervals of the Test lens was below +0.01 logMAR for distance.</non_inferiority_desc>
            <param_type>Least-Square Mean Estimate</param_type>
            <param_value>-0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.099</ci_lower_limit>
            <ci_upper_limit>-0.054</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Near Binocular Visual Acuity</title>
        <description>Near visual acuity was assessed for each subject in both eyes under a high luminance high contrast condition using reduced Guillon-Poling Charts.</description>
        <time_frame>1-Week Follow-up</time_frame>
        <population>All subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Delefilcon A</title>
            <description>All subjects that wore the delefilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Nesofilcon A</title>
            <description>All subjects that wore the nesofilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Near Binocular Visual Acuity</title>
          <description>Near visual acuity was assessed for each subject in both eyes under a high luminance high contrast condition using reduced Guillon-Poling Charts.</description>
          <population>All subjects that completed all study visits without a major protocol deviation.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" spread="0.1084"/>
                    <measurement group_id="O2" value="0.143" spread="0.1117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Statistical superiority was concluded if the upper limit of the confidence intervals of the Test lens was below +0.17 logMAR for near.</non_inferiority_desc>
            <param_type>LS Mean Estimate</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0147</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.112</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Statistical superiority was concluded if the upper limit of the confidence intervals of the Test lens was below +0.17 logMAR for near.</non_inferiority_desc>
            <param_type>LS Mean Estimate</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0147</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.112</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Quality of Vision</title>
        <description>Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>1-Week Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Delefilcon A</title>
            <description>All subjects that wore the delefilcon A lens during either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Nesofilcon A</title>
            <description>All subjects that wore the nesofilcon A lens during either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Quality of Vision</title>
          <description>Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="17.81"/>
                    <measurement group_id="O2" value="49.3" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Statistical superiority was concluded if the lower limit of the confidence intervals of the Test lens was above 32 CLUE points.</non_inferiority_desc>
            <param_type>LS Mean Estimate</param_type>
            <param_value>45.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.2</ci_lower_limit>
            <ci_upper_limit>49.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Statistical superiority was concluded if the lower limit of the confidence intervals of the Test lens was above 32 CLUE points.</non_inferiority_desc>
            <param_type>LS Mean Estimate</param_type>
            <param_value>46.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.1</ci_lower_limit>
            <ci_upper_limit>50.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire duration of the study. Approximately 1 month per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Delefilcon A</title>
          <description>All subjects that wore the delefilcon A lens during either the first or second period of the study.</description>
        </group>
        <group group_id="E2">
          <title>Nesofilcon A</title>
          <description>All subjects that wore the nesofilcon A lens during either the first or second period of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Karkkainen, OD, MS, FAAO- Sr. Principal Research Optometrist</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care Inc.</organization>
      <phone>1-904-443-3402</phone>
      <email>TKarkkai@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

